Sufentanil Citrate Injection Shortage Update

This report provides the latest information regarding the supply status of Sufentanil Citrate Injection, a medication primarily used in analgesia, addiction treatment, and pediatric care. This shortage has been tracked by the FDA since May 2022.

What’s in Shortage

Generic Name: Sufentanil Citrate Injection
Brand Name: SUFENTANIL CITRATE
Dosage Form: Injection
Therapeutic Category: Analgesia/Addiction, Pediatric
Current Status: Current Shortage (Last updated: February 12, 2026)

Which Manufacturers Are Affected

The following manufacturer is listed in the FDA database regarding this medication:

• Hospira, Inc., a Pfizer Company
  • Status: Available
  • Presentation: Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)
  • Contact Information: 844-646-4398

While the manufacturer currently lists the product as available, the medication remains on the FDA’s current shortage list, which may indicate limited supply or regional distribution challenges.

Why There’s a Shortage

No specific reason for the shortage was provided in the source data.

What Patients Should Do

If you or a family member are prescribed Sufentanil Citrate Injection, please consider the following steps:

• Consult Your Healthcare Provider: Always speak with your doctor or healthcare provider regarding your treatment plan. They are best equipped to discuss the impact of this shortage on your care.
• Speak with a Pharmacist: Your pharmacist can provide real-time information on local stock levels and potential procurement timelines.
• Contact the Manufacturer: For specific questions regarding supply dates or distribution, you may contact Hospira/Pfizer at the number provided above.

Disclaimer: This article is for informational purposes only. Patients should consult their healthcare provider for medical advice and to discuss alternative treatment options.

Source

Information provided by the FDA Drug Shortage Database. Initial posting date: May 3, 2022.